Chinese
Newsroom
Events
Newsroom

Leading manufacturer of brachytherapy accessories is now a subsidiary of BEBIG Medical

2013-11-06 Page Views : 499 Author : Admin

Important Notes:

In January 2021, BEBIG Medical GmbH took over the global production and distribution structures of the HDR brachytherapy products of Eckert & Ziegler BEBIG GmbH including Mick Radio-Nuclear Instruments, Inc.

Below news are related to the HDR brachytherapy business and is quoted originally from the website: https://www.ezag.com/home/press/press_releases/detail/?tx_ttnews%5Btt_news%5D=125&cHash=c9c6b19eb96db84f79953289a6f0067e

 

Original Content:

Eckert & Ziegler BEBIG, the medical device division of Eckert & Ziegler AG, is to acquire 100% of the shares in Mick Radio Nuclear Instruments, Inc. (MRNI). One of the leading manufacturers of brachytherapy instrumentation and accessories, the company is based in the US state of New York and generated sales of approximately €4 million in fiscal year 2012/2013. A non-disclosure agreement has been reached regarding the price of the purchase. 

The purchase of MRNI represents another important bridgehead for Eckert & Ziegler’s entry into the US market and complements the recent acquisition of the brachytherapy division of the US company Biocompatibles, Inc. just a few weeks ago, Eckert & Ziegler reported that it had bought the division, rounding out its product portfolio in the area of prostate cancer therapy and gaining an experienced sales team for the North American market.  

Felix Mick, a Swiss engineer and one of the pioneers in the use of radioisotopes for treating cancer (brachytherapy), laid the foundations for MRNI in New York in the 1970s. With the help of Dr. Ulrich Henschke, a radiation oncologist and pioneer in afterloading technology, he developed brachytherapy into an effective treatment option for numerous forms of cancer. MRNI began as a small manufacturing unit in the Bronx and is now the leading manufacturer of applicators. Felix Mick’s contribution to this form of therapy has become legendary.

Around 10% of cancer patients worldwide are treated with brachytherapy, a method in which a radioactive source is placed inside or near the area to be irradiated in the body.

“MRNI is an acclaimed market leader that has an extensive portfolio of patents and offers a high level of innovation in the field of brachytherapy applicators,” explained Dr. Edgar Löffler, Managing Director of Eckert & Ziegler BEBIG s.a. and Member of the Executive Board at Eckert & Ziegler AG. “The acquisition of the brachytherapy division at Biocompatibles Inc. and MRNI, whose clients include all companies and hospitals in the field of brachytherapy, has provided a huge boost for our sales strategy in the US,” Löffler added. 

Felix Mick will continue to support Eckert & Ziegler BEBIG as a technological consultant.

Afterloading is a form of robot-assisted radiotherapy that involves placing a small radioactive source directly into the affected organ. In cervical cancer, for example, the physician inserts a special hollow tube ‒ the applicator ‒ into the patient’s vagina until it reaches the tumor. The applicator is connected to the afterloading equipment by a tube, which contains the miniaturized radioactive source. After that, the physician checks (e.g. with an ultrasound or a CT/MRI) whether the applicator is in the correct position. The physician and medical staff can then leave the treatment room and begin the actual irradiation from the next room. The radiation source passes through the tube to the applicator via a highly flexible cable. Once in position, the afterloader is programmed to direct the source at the area to be treated in gradual steps. How long the source will stay in each dwell position is calculated individually for each type of tumor and enables physicians to adjust the dose to the target volume. This protects the surrounding organs and reduces side effects. Together with recent developments in three-dimensional imaging, computerized treatment planning systems and robot-assisted afterloading devices, this has made brachytherapy a safe and effective form of treatment for many types of cancer.

 

About BEBIG Medical GmbH:

BEBIG Medical GmbH (“BEBIG Medical”) is a global provider of high quality radiation therapy products for cancer treatment headquartered in Berlin, Germany. Preceded by the high dose brachytherapy business unit of Eckert & Ziegler AG, BEBIG Medical has a heritage of more than 40 years’ experience in brachytherapy field and continues to provide affordable healthcare with proven clinical outcomes via strong and viable technology.BEBIG Medical’s US subsidiary, Mick Radio-Nuclear Instruments, Inc., is also known internationally for its manufacturing expertise in the field of applicators and accessories to advance brachytherapy. With a team of professionals and offices in Europe, United States and Asia, the company is empowered to serve customers in more than 65 countries and regions together with a worldwide distribution network.

 

Contact:

Crystal Chen, Chief Commercial Officer: crystal.chen@bebigmedical.com


Related News
sales@bebigmedical.com
+49 30 9487888-10
Robert-Rössle-Str. 10, 13125 Berlin Germany

Copyright © BEBIG Medical. All rights reserved.